1. Volume 10, Issue 9, Pages 872-876 (September 2009)
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials 
Prof David P Dearnaley, FRCP, Prof Malcolm D Mason, FRCP, Prof Mahesh KB Parmar, DPhil, Karen Sanders, BSc, Matthew R Sydes, MSc 
The Lancet Oncology 
Volume 10, Issue 9, Pages (September 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
NHS IC=NHS Information Centre (formerly Office for National Statistics). This figure shows the process of flagging and the data available. All patients on PR04 were flagged before the main, previously reported analyses, but flagging was not done in 190 patients in the PR05 trial who were already known to have died by that point. The NHS IC only provides information on patients who live in England and Wales. Therefore, 50 patients from Scotland and 15 patients from New Zealand have been excluded from these analyses. Similarly, we have excluded five patients from England and Wales who could not be matched with the NHS IC database.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2
Overall survival by group in metastatic disease (PR05; A) and localised disease (PR04; B)
The numbers at risk (alive) are presented at 2-yearly intervals. The numbers of events are presented in parentheses, representing the deaths during these intervals.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Exploratory subgroup analyses of the effect of clodronate in metastatic disease (PR05; A) and in non-metastatic disease (PR04; B), and compared with metastatic disease where all patients received hormone therapy
Alk phos=alkaline phosphatase. HT=hormone therapy. RT=radiotherapy. M0=non-metastatic disease. M1=metastatic disease. WHO PS=World Health Organization performance status. (A) Alkaline phosphatase was dichotomised at a value of 200 IU/L, separating most of the values from a long tail. Serum creatinine (μmol/L) was divided into tertiles.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions